参芪注射液联合化疗及顺铂胸腔灌注治疗非小细胞肺癌恶性胸水的疗效观察-东南大学学报医学版

参芪注射液联合化疗及顺铂胸腔灌注治疗非小细胞肺癌恶性胸水的疗效观察

单位：兰州大学第一医院呼吸科, 甘肃兰州 730000

分类号：R734.2;R561.3

出版年·卷·期（页码）：2016·35·第二期（192-195）

摘要：

目的:观察参芪注射液联合多西他赛/顺铂(DP)方案化疗及胸腔内注射顺铂对伴恶性胸水的非小细胞肺癌(NSCLC)的疗效。方法:将42例NSCLC伴恶性胸腔积液初治患者按入院先后随机分为治疗组(21例)和对照组(21例),两组均采用DP方案化疗,同时引流胸水后胸腔内注入顺铂。治疗组在对照组的基础上于化疗前3 d予以参芪注射液静脉滴注,连用10 d。21 d为1个疗程,共4个疗程。评价胸水控制情况、卡氏评分(KPS)及不良反应。结果:与对照组比较,治疗组胸水控制有效率(PR+CR)高(分别为85.71%、47.62%,P<0.05),KPS改善更好(P<0.05),胃肠道反应、白细胞下降发生率低(P<0.05)。结论:对NSCLC伴恶性胸腔积液患者采用参芪注射液联合DP方案化疗及胸腔内注射顺铂可有效减少胸水产生,改善患者临床症状及生活质量,并减轻化疗毒副反应。

Objective:To observe the effects of Shenqi injection combined with docetaxel/cisplatin(DP) chemotherapy and intrapleural injection of cisplatin in treatment of non-small cell lung cancer(NSCLC) with malignant pleural effusion. Methods:A total number of 42 NSCLC patients with malignant pleural effusion were randomly divided into treatment group and control group, 21 cases in each group. The patients in two groups were received DP chemotherapy and at the same time intrapleural injection of cisplatin were given after the chest drainage of pleural effusion. Control group was treated single chemotherapy, treatment group were combined with intravenous infusion of shenqifuzheng injection before 3 days of the treatment with chemotherapy. The situation of pleural effusion, KPS and adverse reactions were evaluated. Results:Compared with control group, treatment group had high effective rate of controlling pleural effusion(85.71% vs. 47.62% respectively, P<0.05), higher KPS score(P<0.05), lower the incidence of gastrointestinal reactions and adverse reactions(P<0.05). Conclusion:Shenqi injection combined with DP chemotherapy and intrapleural injection of cisplatin can effectively reduce the production of pleural effusion, improve the clinical symptoms and quality of life, reduce the toxicity of chemotherapy in treatment of NSCLC with malignant pleural effusion.

参考文献：

[1] JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] 姚晓军,刘伦旭.肺癌的流行病学及治疗现状[J].现代肿瘤医学,2014,22(8):1982-1986.
[3] 张献怀.解放军总医院第一附属医院遏制非小细胞肺癌恶性胸水有新招[J].老年健康,2014(3):6-6
[4] 边志民.顺铂胸腔灌注联合化疗治疗肺癌并恶性胸水的疗效观察[J].中国卫生标准管理,2015,6(16):99-101.
[5] 刘飞,杭兆康,姜藻,等.香菇多糖联合顺铂与单药顺铂胸腔灌注治疗恶性胸腔积液的疗效对比研究[J].东南大学学报:医学版,2011,30(2):367-369.
[6] PARK D S,KIM D,HWANG K E,et al.Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions[J].Yonsei Med J,2013,54(2):396-402.
[7] TIAN P,SHEN Y,WAN C,et al.Diagnostic value of survivin for malignant pleural effusion:a clinical study and meta-analysis[J].Int J Clin Exp Pathol,2014,7(9):5880-5887.
[8] 刘颖,薄晓霞.鸦胆子油乳剂联合顺铂胸腔灌注治疗恶性胸水的临床研究[J].现代医学,2014,42(5):554-555.
[9] 田金徽,赵晔,李金龙,等.10种中药注射剂联合长春瑞滨+顺铂化疗方案治疗非小细胞肺癌的网状Meta分析[J].中国药物评价,2015,32(1):45-49.
[10] QI F,ZHAO L,ZHOU A,et al.The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatm ent instead of only terminal stage of cancer[J].Biosci Trends,2015,9(1):16-34.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录